Table of Contents
Structure and Synthetic Origin
Tesamorelin is a 44-amino acid peptide sharing the same sequence as endogenous human GHRH(1-44)-NH2, with one key modification: the addition of a trans-3-hexenoic acid group at the N-terminal end of the chain. This modification was introduced during pharmaceutical development to extend the compound's half-life relative to native GHRH, which is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) at the Tyr-Ala bond near the N-terminus.
The trans-3-hexenoic acid modification shields the N-terminus from DPP-IV-mediated degradation without substantially disrupting the peptide's receptor binding geometry. From a synthesis standpoint, this makes Tesamorelin more challenging to manufacture at high purity than simpler GHRH fragments — a fact that has direct implications for quality assessment when sourcing the compound for laboratory use.
Researchers should confirm that any supplier is providing authentic Tesamorelin with the correct N-terminal modification, verified by mass spectrometry alongside HPLC purity data. Molecular weight confirmation is particularly important for this compound due to the structural complexity introduced by the fatty acid modification.
The GHRH Axis in Research Contexts
Growth hormone-releasing hormone is produced in the hypothalamus and acts on somatotroph cells in the anterior pituitary via the GHRH receptor (GHRHR). Binding of GHRH to GHRHR stimulates the synthesis and pulsatile secretion of growth hormone (GH). GH then acts on peripheral tissues both directly and through induction of insulin-like growth factor 1 (IGF-1) in the liver.
In laboratory research, GHRH-axis compounds like Tesamorelin are studied as tools for investigating this regulatory pathway. Research questions frequently involve understanding how the GHRH receptor responds to structural analogues, how downstream GH/IGF-1 signalling is modulated, and how various intervention strategies interact with baseline axis activity in different model systems.
The performance peptide category on the Peptides Canada catalog includes Tesamorelin alongside other GHRH-axis compounds used in research. Researchers can also explore related compounds such as Sermorelin and Ipamorelin for comparative pathway studies.
Summary of Published Research
The peer-reviewed literature on Tesamorelin spans multiple decades, with early preclinical work establishing receptor binding affinity and in vitro activity, followed by controlled clinical investigations. Researchers interested in reviewing the evidentiary landscape will find a substantial body of work in journals covering endocrinology, metabolism, and pharmacology.
Key areas documented in published studies include the compound's interaction with pituitary GHRH receptors, dose-dependent modulation of GH secretion patterns in controlled settings, and observations related to visceral adipose tissue composition in specific clinical populations. These studies were conducted under strictly controlled conditions with defined endpoints and subject populations.
For researchers building literature reviews or protocol foundations, PubMed and Embase provide access to the indexed primary literature. Laboratory researchers should evaluate published methodology sections carefully when designing their own in vitro or ex vivo studies involving Tesamorelin, paying particular attention to concentration ranges, vehicle selection, and assay conditions used in cited work.
Stability and Handling Characteristics
Tesamorelin, like most synthetic GHRH analogues, presents stability challenges that researchers must account for during laboratory handling. The compound is supplied as a lyophilized (freeze-dried) white powder and should be stored under conditions that prevent moisture absorption and thermal degradation.
Recommended storage for lyophilized Tesamorelin is at -20°C or below, protected from light. Once reconstituted, the solution should be stored at 2–8°C and used within a short timeframe consistent with published stability data. Researchers should consult their institution's standard operating procedures for peptide handling and refer to the comprehensive peptide storage guide in this Research Hub for general best practices.
The trans-3-hexenoic acid modification at the N-terminus does not substantially alter the lyophilization behaviour of Tesamorelin relative to unmodified GHRH analogues. However, researchers should monitor reconstituted solutions for signs of aggregation or precipitation, particularly if storage conditions deviate from recommended parameters.
Quality Benchmarks and COA Interpretation
Given the structural complexity of Tesamorelin — specifically the N-terminal fatty acid modification — quality documentation for this compound should include both HPLC purity data and mass spectrometry (MS) confirmation. HPLC alone, while necessary, is insufficient to confirm the presence of the trans-3-hexenoic acid modification; MS data provides the molecular weight confirmation that validates structural identity.
Researchers should expect the following from a complete Tesamorelin COA:
- HPLC purity — ≥98% by area for research-grade material
- Mass spectrometry — confirming observed molecular weight consistent with Tesamorelin (MW approximately 5135.9 Da)
- Appearance — white to off-white lyophilized powder
- Water content — ideally reported via Karl Fischer analysis
- Peptide content — distinguishing actual peptide content from water and salt contribution to total mass
The lab testing and COA page provides further guidance on interpreting quality documentation. The related Research Hub article on how to read a COA covers each of these data points in detail.
Sourcing Tesamorelin for Canadian Research
Canadian researchers seeking Tesamorelin for laboratory use should apply standard supplier evaluation criteria: third-party HPLC and MS testing, documented chain of custody from synthesis to shipment, and transparent COA availability before purchase. The structural complexity of Tesamorelin makes quality documentation more critical than for simpler peptides — the N-terminal modification must be confirmed, not assumed.
Peptides Canada supplies Tesamorelin 10mg for research and laboratory use, with HPLC-verified purity and third-party testing documentation available on request. All orders ship within Canada with appropriate cold-chain handling. Visit the Tesamorelin product page for current specifications and pricing.
Researchers with questions about documentation, handling requirements, or compatibility with existing protocols are encouraged to reach out through the contact page before placing an order. For common research setup questions, the FAQ covers reconstitution, storage, and sourcing topics in detail.